Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Plasmolipin is a highly hydrophobic transmembrane protein encoded by the *PLLP* gene on chromosome 16, primarily localized in the myelin sheath and plasma membrane of nervous system cells[1][3]. It contains four transmembrane domains forming the MARVEL domain, facilitating membrane organization, vesicle trafficking, and myelin maintenance[1]. Plasmolipin is important in nervous system development, intracellular protein sorting, and is implicated in myelin assembly, Notch signaling, and the formation of lipid rafts[1][7]. Changes in plasmolipin expression have been associated with neurodegenerative diseases (such as Alzheimer’s and schizophrenia), certain cancers, and possibly metabolic disorders like type 2 diabetes[1]. While it shares some features with tetraspanins and other myelin proteins (e.g., MAL, PLP), it is not an ion channel or classical receptor and currently lacks direct therapeutic targeting by drugs[1][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Plasmolipin (PLLP).